Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Markus Pfirrmann, Francois-Xavier Mahon, MD PhD, Joelle Guilhot, PhD, Johan Richter, MD PhD, Francis J. Giles, MD MB, FRCPath, Andreas Hochhaus, MD, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Giuseppe Saglio, MD PhD, Weiping Deng, Darshan Dalal, MPH, MD PhD, Susanne Saussele, MD

Blood (2017) 130 (Supplement 1): 1601.

https://doi.org/10.1182/blood.V130.Suppl_1.1601.1601

Published: 2017

Journal Articles

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Giuseppe Saglio, MD PhD, Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 1598.

https://doi.org/10.1182/blood.V130.Suppl_1.1598.1598

Published: 2017

Journal Articles

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francois-Xavier Mahon, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Giuseppe Saglio, MD PhD

Blood (2017) 130 (Supplement 1): 2878.

https://doi.org/10.1182/blood.V130.Suppl_1.2878.2878

Published: 2017

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, MD, Maria Teresa Gómez Casares, MDPhD, Jesper Stentoft, MD PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Valentin García-Gutiérrez, MD, Norbert Gattermann, MD, Wieslaw Wiktor-Jedrzejczak, MD, Philipp D. Le Coutre, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MB, MD FRCPI, FRCPath, Jerald P. Radich, David M. Ross, MBBS, PhD FRACP, FRCPA, Hans D. Menssen, MD PhD, Weiping Deng, Patricia Brandt, Ari Gnanasakthy, MBA, MSc, Veronique Bedoucha, Giuseppe Saglio, MD

Blood (2016) 128 (22): 3066.

https://doi.org/10.1182/blood.V128.22.3066.3066

Published: 2016

Journal Articles

Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Andreas Hochhaus, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Richard A. Larson, MD, Lilia Taningco, MSc, Weiping Deng, Hans D Menssen, MD PhD, Hagop M. Kantarjian, MD

Blood (2015) 126 (23): 2781.

https://doi.org/10.1182/blood.V126.23.2781.2781

Published: 2015

Journal Articles

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Richard A. Larson, Dong-Wook Kim, MD PhD, Surapol Issaragrilsil, MD, Philipp le Coutre, MD, Pedro Enrique Dorlhiac Llacer, Gabriel Etienne, MD PhD, Richard E. Clark, MD, Ian Flinn, Hirohisa Nakamae, Andreas Hochhaus, MD, Giuseppe Saglio, MD, Hagop M. Kantarjian, Breanne Donohue, PharmD, Weiping Deng, PhD, Hans D. Menssen, MD PhD, Timothy P. Hughes, MD

Blood (2014) 124 (21): 4541.

https://doi.org/10.1182/blood.V124.21.4541.4541

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Email alerts

ASH Publications

American Society of Hematology

Update search

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only